全文获取类型
收费全文 | 21402篇 |
免费 | 1412篇 |
国内免费 | 146篇 |
专业分类
耳鼻咽喉 | 183篇 |
儿科学 | 523篇 |
妇产科学 | 399篇 |
基础医学 | 2518篇 |
口腔科学 | 819篇 |
临床医学 | 1994篇 |
内科学 | 4589篇 |
皮肤病学 | 410篇 |
神经病学 | 1311篇 |
特种医学 | 480篇 |
外国民族医学 | 5篇 |
外科学 | 2734篇 |
综合类 | 687篇 |
一般理论 | 15篇 |
预防医学 | 1945篇 |
眼科学 | 832篇 |
药学 | 2051篇 |
中国医学 | 258篇 |
肿瘤学 | 1207篇 |
出版年
2024年 | 22篇 |
2023年 | 248篇 |
2022年 | 634篇 |
2021年 | 1255篇 |
2020年 | 795篇 |
2019年 | 968篇 |
2018年 | 1133篇 |
2017年 | 818篇 |
2016年 | 853篇 |
2015年 | 870篇 |
2014年 | 1165篇 |
2013年 | 1342篇 |
2012年 | 1875篇 |
2011年 | 1917篇 |
2010年 | 1096篇 |
2009年 | 835篇 |
2008年 | 1272篇 |
2007年 | 1137篇 |
2006年 | 969篇 |
2005年 | 822篇 |
2004年 | 655篇 |
2003年 | 553篇 |
2002年 | 471篇 |
2001年 | 122篇 |
2000年 | 118篇 |
1999年 | 114篇 |
1998年 | 71篇 |
1997年 | 61篇 |
1996年 | 56篇 |
1995年 | 52篇 |
1994年 | 33篇 |
1993年 | 44篇 |
1992年 | 52篇 |
1991年 | 42篇 |
1990年 | 45篇 |
1989年 | 39篇 |
1988年 | 38篇 |
1987年 | 28篇 |
1986年 | 25篇 |
1985年 | 28篇 |
1984年 | 32篇 |
1983年 | 30篇 |
1982年 | 21篇 |
1981年 | 14篇 |
1980年 | 22篇 |
1979年 | 17篇 |
1978年 | 17篇 |
1976年 | 17篇 |
1975年 | 15篇 |
1974年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
121.
A novel frame shift mutation in the HMG box of the SRY gene in a patient with complete 46,XY pure gonadal dysgenesis. 总被引:1,自引:0,他引:1
Richard Kellermayer László Halvax Márta Czakó Mohammad Shahid Varinderpal S Dhillon Syed Akhtar Husain Norbert Süle Eva G?m?ri Mariann Mammel Gy?rgy Kosztolányi 《Diagnostic molecular pathology》2005,14(3):159-163
Pure gonadal dysgenesis or Swyer syndrome is a sex-reversal disorder resulting from embryonic testicular regression sequences especially during the first few weeks of fetal life and is induced by mutations in the SRY gene. In the present report, we describe a nonmosaic XY sex-reversed female with pure gonadal dysgenesis. Molecular analysis using sequential PCR to detect Y chromosomal microdeletions showed the presence of SRY, ZFY and AZFa, b and c regions. Automated sequencing of the SRY region revealed a new mutation (deletion of A (adenine) in codon 82 at position +244), leading to a frame shift mutation within the helix I of the HMG-box domain. This mutation generates a truncated protein and is very likely to produce an impairment of SRY DNA binding activity. The present findings further support the functional importance of the putative DNA binding activity of the SRY HMG-box domain. 相似文献
122.
Shahid M Dhillion VS Jain N Hedau S Diwakar S Sachdeva P Batra S Das BC Husain SA 《Molecular human reproduction》2004,10(7):521-526
123.
Ramaseshan R Kohli KS Zhang TJ Lam T Norlinger B Hallil A Islam M 《Physics in medicine and biology》2004,49(17):4031-4048
The commercially available microMOSFET dosimeter was characterized for its dosimetric properties in radiotherapy treatments. The MOSFET exhibited excellent correlation with the dose and was linear in the range of 5-500 cGy. No measurable effect in response was observed in the temperature range of 20-40 degrees C. No significant change in response was observed by changing the dose rate between 100 and 600 monitor units (MU) min(-1) or change in the dose per pulse. A 3% post-irradiation fading was observed within the first 5 h of exposure and thereafter it remained stable up to 60 h. A uniform energy response was observed in the therapy range between 4 MV and 18 MV. However, below 0.6 MeV (Cs-132), the MOSFET response increased with the decrease in energy. The MOSFET also had a uniform dose response in 6-20 MeV electron beams. The directional dependence of MOSFET was within +/-2% for all the energies studied. The inherent build-up of the MOSFET was evaluated dosimetrically and found to have varying water equivalent thickness, depending on the energy and the side of the beam entry. At depth, a single calibration factor obtained by averaging the MOSFET response over different field sizes, energies, orientation and depths reproduced the ion chamber measured dose to within 5%. The stereotactic and the penumbral measurements demonstrated that the MOSFET could be used in a high gradient field such as IMRT. The study showed that the microMOSFET dosimeter could be used as an in vivo dosimeter to verify the dose delivery to the patient to within +/-5%. 相似文献
124.
125.
Shariati-Bafghi Seyedeh-Elaheh Rashidkhani Bahram Salehi Fadardi Javad Safarian Mohammad Edalatian Javad Ranjbar Golnaz Nematy Mohsen 《Quality of life research》2022,31(3):789-802
Quality of Life Research - Examining the associations of a-posteriori-defined dietary patterns and health-related quality of life (HRQOL) among Iranian adolescents. This cross-sectional study was... 相似文献
126.
Hasan M. Tasdik Hossain Sahadat Gupta Rajat Das Podder Vivek Mowri Naima Afroz Ghosh Anindita Mahmood Hassan Rushekh Ahmmed Faisal Khatun M. S. T. Halima Nodi Rhedeya Nury Koly Kamrun Nahar Yasmeen Sharmeen Islam Nazrul 《Zeitschrift fur Gesundheitswissenschaften》2022,30(2):465-473
Journal of Public Health - Depression is a major morbidity and the most common mental disorder among the medical students in medical schools globally. Undergraduate students suffer stress more due... 相似文献
127.
Suraj Suresh Mohammad Siddiqui Mouhanna Abu Ghanimeh Jessica Jou Stephen Simmer Vivek Mendiratta Sarah Russell Mustafa Al-Shammari Abigail Chatfield Eva Alsheik Duyen Dang Jeffrey Genaw Tobias Zuchelli 《Obesity research & clinical practice》2021,15(2):172-176
BackgroundAlthough recent studies have shown an association between obesity and adverse coronavirus disease 2019 (COVID-19) patient outcomes, there is a paucity in large studies focusing on hospitalized patients. We aimed to analyze outcomes associated with obesity in a large cohort of hospitalized COVID-19 patients.MethodsWe performed a retrospective study at a tertiary care health system of adult patients with COVID-19 who were admitted between March 1 and April 30, 2020. Patients were stratified by body mass index (BMI) into obese (BMI ≥ 30 kg/m 2) and non-obese (BMI < 30 kg/m 2) cohorts. Primary outcomes were mortality, intensive care unit (ICU) admission, intubation, and 30-day readmission.ResultsA total of 1983 patients were included of whom 1031 (51.9%) had obesity and 952 (48.9%) did not have obesity. Patients with obesity were younger (P < 0.001), more likely to be female (P < 0.001) and African American (P < 0.001) compared to patients without obesity. Multivariable logistic models adjusting for differences in age, sex, race, medical comorbidities, and treatment modalities revealed no difference in 60-day mortality and 30-day readmission between obese and non-obese groups. In these models, patients with obesity had increased odds of ICU admission (adjusted OR, 1.37; 95% CI, 1.07?1.76; P = 0.012) and intubation (adjusted OR, 1.37; 95% CI, 1.04?1.80; P = 0.026).ConclusionsObesity in patients with COVID-19 is independently associated with increased risk for ICU admission and intubation. Recognizing that obesity impacts morbidity in this manner is crucial for appropriate management of COVID-19 patients. 相似文献
128.
Mohammad Abumayyaleh Iván J. Núñez Gil Ibrahim El-Battrawy Vicente Estrada Víctor Manuel Becerra-Muñoz Alvaro Aparisi Inmaculada Fernández-Rozas Gisela Feltes Ramón Arroyo-Espliguero Daniela Trabattoni Javier López-País Martino Pepe Rodolfo Romero Diego Raúl Villavicencio García Carloalberto Biole Thamar Capel Astrua Charbel Maroun Eid Emilio Alfonso Ibrahim Akin 《Obesity research & clinical practice》2021,15(3):275-280
BackgroundObesity has been described as a protective factor in cardiovascular and other diseases being expressed as ‘obesity paradox’. However, the impact of obesity on clinical outcomes including mortality in COVID-19 has been poorly systematically investigated until now. We aimed to compare clinical outcomes among COVID-19 patients divided into three groups according to the body mass index (BMI).MethodsWe retrospectively collected data up to May 31st, 2020. 3635 patients were divided into three groups of BMI (<25 kg/m2; n = 1110, 25?30 kg/m2; n = 1464, and >30 kg/m2; n = 1061). Demographic, in-hospital complications, and predictors for mortality, respiratory insufficiency, and sepsis were analyzed.ResultsThe rate of respiratory insufficiency was more recorded in BMI 25?30 kg/m2 as compared to BMI < 25 kg/m2 (22.8% vs. 41.8%; p < 0.001), and in BMI > 30 kg/m2 than BMI < 25 kg/m2, respectively (22.8% vs. 35.4%; p < 0.001). Sepsis was more observed in BMI 25?30 kg/m2 and BMI > 30 kg/m2 as compared to BMI < 25 kg/m2, respectively (25.1% vs. 42.5%; p = 0.02) and (25.1% vs. 32.5%; p = 0.006). The mortality rate was higher in BMI 25?30 kg/m2 and BMI > 30 kg/m2 as compared to BMI < 25 kg/m2, respectively (27.2% vs. 39.2%; p = 0.31) (27.2% vs. 33.5%; p = 0.004). In the Cox multivariate analysis for mortality, BMI < 25 kg/m2 and BMI > 30 kg/m2 did not impact the mortality rate (HR 1.15, 95% CI: 0.889?1.508; p = 0.27) (HR 1.15, 95% CI: 0.893?1.479; p = 0.27). In multivariate logistic regression analyses for respiratory insufficiency and sepsis, BMI < 25 kg/m2 is determined as an independent predictor for reduction of respiratory insufficiency (OR 0.73, 95% CI: 0.538?1.004; p = 0.05).ConclusionsHOPE COVID-19-Registry revealed no evidence of obesity paradox in patients with COVID-19. However, Obesity was associated with a higher rate of respiratory insufficiency and sepsis but was not determined as an independent predictor for a high mortality. 相似文献
129.
130.
Many dietary guidelines emphasise “mostly” whole grain food choices as part of an overall healthy eating pattern based on evidence for enhancing nutritional status and reducing chronic disease. Still, countries including Australia fall short of their consumption targets. Furthermore, healthcare cost savings associated with increasing the consumption of whole grains in alignment with the Daily Target Intake (DTI) recommendation of 48 g are unknown. The aim of this study was to assess the potential savings in costs of healthcare and lost productivity associated with a reduction in the incidence of Type 2 Diabetes Mellitus (T2DM) and cardiovascular disease (CVD) through meeting the 48 g DTI recommendation for whole grains among the Australian adult population (>20 years). A three-step cost-of-illness analysis was conducted using input parameters from: 1) estimates of proportions of consumers (5%, 15%, 50%, and 100%) who would increase their current intake of whole grains to meet the recommended DTI in Australia; 2) relative reductions in risk of T2DM and CVD associated with specific whole grain consumption, as reported in meta-analysis studies; and 3) data on costs of healthcare and productivity loss based on monetary figures by national healthcare authorities. A very pessimistic (5% of the population) through to universal (100% of the population) adoption of the recommended DTI was shown to potentially yield AUD 37.5 (95% CI 22.3–49.3) to AUD 750.7 (95% CI 445.7–985.2) million, and AUD 35.9 (95% CI 8.3–60.7) to AUD 717.4 (95% CI 165.5–1214.1) million in savings on annual healthcare and lost productivity costs for T2DM and CVD, respectively. Given such economic benefits of the recommended consumption of whole grains, in exchange for refined grains, there is a real opportunity to facilitate relevant socioeconomic cost-savings for Australia and reductions in disease. These results are suggestive of a much greater opportunity to communicate the need for dietary change at all levels, but particularly through food-based dietary guidelines and front-of-pack labelling initiatives. 相似文献